NCT01215487View on ClinicalTrials.gov

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Chronic Myeloid Leukemia
Interventions
PROCEDURE

Stem Cell and Mutational Assay

Laboratory blood testing

Trial Locations (1)

V5Z 1M9

Leukemia BMT program of BC, Vancouver General Hospital, Hematology Research and Clinical Trials Unit, Vancouver

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of British Columbia

OTHER